Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)
Conditions: Epidermolysis Bullosa; Recessive Dystrophic Epidermolysis Bullosa Intervention: Biological: EB-101 Sponsor: Abeona Therapeutics, Inc Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials